Figure S9 from Direct Co-Targeting of Bcl-xL and Mcl-1 Exhibits Synergistic Effects in AR-V7–Expressing CRPC Models

Key Points

• Combined treatment with XZ739 and S63845 significantly alters protein levels in CRPC models, and ensures a synergistic effect on tumor response.
• The protein level changes in AR-V7-expressing CRPC were observed after just 24 hours of treatment, showing promising efficacy for this combination.
• Observation from protein level changes underscores the potential of targeting Bcl-xL and Mcl-1 together in cancer therapies for CRPC.
• These findings point to the need for further exploration of combined targeting strategies in therapeutic applications for prostate cancer.